glp-1 reimbursement news drugs pricing and changes | Noah V. posted on the topic NEW: Tricare For Life &

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Gcg undergoes tissue-specific posttranslational modification by prohormone convertases (PC)

| From small molecule GLP-1R Agonists to non-Ab PD-L1 Inhibitors, our latest patent review at Drug Hunter showcases a diverse array of chemical matter that are captivating drug hunters' interest

[PubMed] [Google Scholar] 22.Moody A.J., Markussen J., Fries A.S., Steenstrup C., Sundby F

Sarosiek I, Davis B, Eichler E, McCallum RW

This distinction has direct implications for in vitro receptor research native GLP-1 provides a physiologically authentic agonist reference for local/paracrine GLP-1R signalling studies, distinct from the systemic receptor engagement profile of long-acting GLP-1RA analogues